27670600|t|Risk and Predictors of Variceal Bleeding in Cirrhosis Patients Receiving Primary Prophylaxis With Non-Selective Beta-Blockers
27670600|a|Prior studies have demonstrated the efficacy of non-selective beta-blockers (NSBB) in preventing first variceal bleeding in patients with cirrhosis. However, little is known about the overall effectiveness of NSBB in routine clinical care. We conducted a retrospective cohort study of cirrhotic patients without prior bleeding who initiated a NSBB (propranolol, nadolol) at any Veterans Administration facility between 2008 and 2013. The primary outcome was variceal bleeding within 12 months. We conducted Cox-proportional hazards analyses to identify demographic, clinical, and NSBB -related (type of NSBB, mean dose, dose change, and heart rate response) factors associated with variceal bleeding. Of 5,775 patients, 678 (11.7%) developed variceal bleeding. Mean daily dose of NSBB was <40 mg in 58.8%, 18.1% had either upward or downward titration in NSBB dose, and 9.8% had hemodynamic response. Patients who were younger, with ascites, greater medical comorbidity, and higher MELD (Model for end-stage liver disease) scores had a higher risk of variceal bleeding. Patients on a higher daily dose (>60 vs. <40 mg, adjusted hazard ratio (HR) 0.64; 95% confidence interval (CI): 0.51-0.81), who had either upward or downward dose titration (adjusted HR 0.69; 95% CI: 0.52-0.90 and 0.64; 95% CI 0.45-0.90, respectively), and those who achieved hemodynamic response (adjusted HR 0.75; 95% CI =0.57-1.0) had lower risk. Approximately 12% of patients bled while being on NSBB for primary prophylaxis. A higher NSBB dose and dose titration were protective; yet most patients did not have the NSBB dose titrated to the recommended levels. Our data highlight the need for careful monitoring of cirrhotic patients on NSBB.
27670600	0	4	Risk	T078	C0035647
27670600	9	19	Predictors	T078	C2698872
27670600	23	40	Variceal Bleeding	T046	C0333106
27670600	44	53	Cirrhosis	T047	C1623038
27670600	54	62	Patients	T101	C0030705
27670600	73	92	Primary Prophylaxis	T170	C0033107
27670600	98	125	Non-Selective Beta-Blockers	UnknownType	C0360148
27670600	162	170	efficacy	T080	C1280519
27670600	174	201	non-selective beta-blockers	UnknownType	C0360148
27670600	203	207	NSBB	UnknownType	C0360148
27670600	229	246	variceal bleeding	T046	C0333106
27670600	250	258	patients	T101	C0030705
27670600	264	273	cirrhosis	T047	C1623038
27670600	318	331	effectiveness	T080	C1280519
27670600	335	339	NSBB	UnknownType	C0360148
27670600	351	364	clinical care	T058	C0086388
27670600	381	407	retrospective cohort study	T062	C2985505
27670600	411	420	cirrhotic	T047	C1623038
27670600	421	429	patients	T101	C0030705
27670600	444	452	bleeding	T046	C0019080
27670600	469	473	NSBB	UnknownType	C0360148
27670600	475	486	propranolol	T109,T121	C0033497
27670600	488	495	nadolol	T109,T121	C0027302
27670600	504	536	Veterans Administration facility	T073,T093	C0020030
27670600	572	579	outcome	T169	C1274040
27670600	584	601	variceal bleeding	T046	C0333106
27670600	612	618	months	T079	C0439231
27670600	633	666	Cox-proportional hazards analyses	T081,T170	C0033489
27670600	679	690	demographic	T078	C0011292
27670600	692	700	clinical	T080	C0205210
27670600	706	710	NSBB	UnknownType	C0360148
27670600	729	733	NSBB	UnknownType	C0360148
27670600	740	744	dose	T081	C0178602
27670600	746	757	dose change	T061	C0554834
27670600	763	782	heart rate response	T201	C1997754
27670600	792	807	associated with	T080	C0332281
27670600	808	825	variceal bleeding	T046	C0333106
27670600	836	844	patients	T101	C0030705
27670600	868	885	variceal bleeding	T046	C0333106
27670600	892	902	daily dose	T081	C2348070
27670600	906	910	NSBB	UnknownType	C0360148
27670600	949	955	upward	T082	C1282911
27670600	959	967	downward	T082	C0205104
27670600	968	977	titration	T059	C0162621
27670600	981	985	NSBB	UnknownType	C0360148
27670600	986	990	dose	T081	C0178602
27670600	1005	1025	hemodynamic response	T042	C0019010
27670600	1027	1035	Patients	T101	C0030705
27670600	1045	1052	younger	T079	C0332239
27670600	1059	1066	ascites	T033	C0003962
27670600	1084	1095	comorbidity	T078	C0009488
27670600	1108	1112	MELD	T185	C3826979
27670600	1114	1147	Model for end-stage liver disease	T185	C3826979
27670600	1149	1155	scores	T170	C1718072
27670600	1169	1173	risk	T078	C0035647
27670600	1177	1194	variceal bleeding	T046	C0333106
27670600	1196	1204	Patients	T101	C0030705
27670600	1217	1227	daily dose	T081	C2348070
27670600	1254	1266	hazard ratio	T081	C2985465
27670600	1268	1270	HR	T081	C2985465
27670600	1282	1301	confidence interval	T081	C0009667
27670600	1303	1305	CI	T081	C0009667
27670600	1335	1341	upward	T082	C1282911
27670600	1345	1353	downward	T082	C0205104
27670600	1354	1358	dose	T081	C0178602
27670600	1359	1368	titration	T059	C0162621
27670600	1379	1381	HR	T081	C2985465
27670600	1392	1394	CI	T081	C0009667
27670600	1420	1422	CI	T081	C0009667
27670600	1472	1492	hemodynamic response	T042	C0019010
27670600	1503	1505	HR	T081	C2985465
27670600	1516	1518	CI	T081	C0009667
27670600	1540	1544	risk	T078	C0035647
27670600	1567	1575	patients	T101	C0030705
27670600	1576	1580	bled	T046	C0019080
27670600	1596	1600	NSBB	UnknownType	C0360148
27670600	1605	1624	primary prophylaxis	T170	C0033107
27670600	1635	1639	NSBB	UnknownType	C0360148
27670600	1640	1644	dose	T081	C0178602
27670600	1649	1653	dose	T081	C0178602
27670600	1654	1663	titration	T059	C0162621
27670600	1690	1698	patients	T101	C0030705
27670600	1716	1720	NSBB	UnknownType	C0360148
27670600	1721	1725	dose	T081	C0178602
27670600	1726	1734	titrated	T059	C0162621
27670600	1802	1812	monitoring	T058	C1283169
27670600	1816	1825	cirrhotic	T047	C1623038
27670600	1826	1834	patients	T101	C0030705
27670600	1838	1842	NSBB	UnknownType	C0360148